Financial Performance - The company's operating revenue for Q3 2021 was CNY 2,194,107,859.99, representing a year-on-year increase of 15.42%[7] - The net profit attributable to shareholders for the same period was CNY 242,993,711.50, reflecting a growth of 25.58% compared to the previous year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 197,138,445.54, with a slight decrease of 0.01%[7] - The basic earnings per share for Q3 2021 was CNY 0.25, an increase of 25.00% year-on-year[10] - Total operating revenue for the first three quarters of 2021 reached CNY 6,811,651,988.14, an increase of 25.4% compared to CNY 5,429,552,436.20 in the same period of 2020[27] - The company's net profit for the current period reached ¥685,910,072.55, an increase from ¥590,636,841.80 in the previous period, representing a growth of approximately 16.5%[31] - Operating profit rose to ¥871,046,107.37 compared to ¥702,111,675.92, reflecting an increase of approximately 24.1%[31] - The total comprehensive income for the period was ¥677,041,003.36, up from ¥592,987,978.33, indicating a growth of around 14.2%[33] - Basic earnings per share improved to ¥0.78 from ¥0.65, representing an increase of approximately 20%[33] - The company reported a total revenue from sales of goods and services amounting to ¥6,708,787,005.05, compared to ¥5,641,252,469.38, which is an increase of approximately 18.9%[37] Assets and Liabilities - The total assets at the end of the reporting period amounted to CNY 11,935,108,371.46, up 13.66% from the end of the previous year[10] - The company's total assets as of September 30, 2021, amounted to CNY 11,935,108,371.46, compared to CNY 10,500,457,880.84 at the end of 2020, reflecting a growth of 13.7%[25] - Current assets totaled CNY 6,177,338,144.47, an increase of 20.7% from CNY 5,118,012,434.82 in the previous year[22] - The company's total liabilities reached CNY 3,013,648,506.07, an increase of 21.9% compared to CNY 2,470,417,073.24 in the previous year[26] - Total liabilities were CNY 2,470,417,073.24, indicating a consistent financial structure[44] - The total assets reached CNY 10,500,457,880.84, remaining stable compared to the previous reporting period[41] Shareholder Information - The equity attributable to shareholders reached CNY 8,456,476,483.36, marking a 10.19% increase compared to the previous year[10] - The equity attributable to shareholders of the parent company was CNY 8,456,476,483.36, compared to CNY 7,674,560,932.92, reflecting a growth of 10.1%[27] - The company reported a total of 72,001 common shareholders at the end of the reporting period[15] - The top shareholder, New Changxing Investment Development Co., Ltd., held 21.57% of the shares, totaling 208,192,361 shares[15] - Total equity attributable to shareholders reached approximately ¥7.67 billion[47] - The company holds a total equity of approximately ¥8.03 billion[47] Cash Flow - The net cash flow from operating activities for the year-to-date was CNY 453,134,252.53, down 39.19% year-on-year due to increased VAT and income tax payments[10][14] - Cash flow from operating activities generated ¥453,134,252.53, a decrease from ¥745,121,054.12 in the previous period, showing a decline of about 39.2%[37] - Cash inflow from financing activities amounted to CNY 1,007,323,382.00, down from CNY 1,409,690,000.00[39] - Net cash flow from financing activities was CNY 253,966,243.15, a recovery from CNY -84,546,086.90 in the prior period[39] - Cash flow from investment activities totaled CNY 1,713,157,896.85, an increase from CNY 1,240,192,904.22 in the previous period[39] - Net cash flow from investment activities was negative at CNY -688,013,409.58, compared to CNY -82,108,097.45 previously[39] Expenses - Total operating costs for the first three quarters of 2021 were CNY 5,966,861,959.15, up 25.0% from CNY 4,777,598,052.40 in the previous year[27] - Research and development expenses increased significantly to ¥692,647,517.23 from ¥395,225,544.71, marking a rise of about 75.4%[31] - Financial expenses increased to ¥51,751,856.25 from ¥33,846,511.02, which is an increase of about 52.9%[31] Other Financial Metrics - The company received government subsidies amounting to CNY 48,556,037.83 year-to-date, which are closely related to its normal business operations[11] - The company recorded a net loss from minority interests of ¥64,704,775.60, compared to a loss of ¥29,897,459.01 in the previous period, reflecting a worsening of approximately 116.5%[31] - Cash and cash equivalents stood at CNY 1,632,665,283.12, slightly up from CNY 1,628,915,874.50[22] - The company's cash and cash equivalents at the end of the period were CNY 1,632,665,283.12, slightly down from CNY 1,854,252,629.72[39] - Accounts receivable stood at CNY 1,622,780,758.78, an increase of 38.0% from CNY 1,175,094,128.67 in the previous year[22] - Inventory as of September 30, 2021, was CNY 1,638,677,291.56, up from CNY 1,479,961,797.93, indicating a growth of 10.7%[22]
浙江医药(600216) - 2021 Q3 - 季度财报